<DOC>
	<DOCNO>NCT00606281</DOCNO>
	<brief_summary>The primary objective trial evaluate clinical efficacy safety aripiprazole comparison placebo patient Bipolar I Disorder experience manic mixed episode .</brief_summary>
	<brief_title>A Multicenter , Randomized , Double-blind , Placebo-controlled , Parallel Group-comparison Trial Aripiprazole Treatment Patients With Bipolar Disorder Experiencing Manic Mixed Episode</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Trial subject men woman age 18 age 65 turn 65 trial . Patients ability understand provide inform consent examination , observation , evaluation process specify protocol , sign informed consent form base full understanding trial . Patients meet DSMIVTR criterion manic mixed episode diagnose `` 296.4x Bipolar I Disorder recent episode manic '' `` 296.6x Bipolar I Disorder recent episode mixed '' Patients YMRS total score 20 Patients present clinical picture and/or history consistent DSMIVTR diagnosis : Delirium , dementia , amnestic disorder , cognitive disorder Schizophrenia psychotic disorder Personality disorder Patients experience first manic mixed episode Patients whose current manic episode last 4 week Patients psychotic symptom clearly due another general medical condition direct physiological effect substance Patients meet DSMIVTR criterion substancerelated disorder within 3 month ( 90 day ) prior inform consent ( exclude caffeine nicotinerelated disorder , include abuse benzodiazepine ) Patients receive ECT treatment within 8 week prior inform consent Patients expect require administration ultrashortacting shortacting benzodiazepine receptor agonist hypnotic antianxiety drug ( See ( 1 ) 4.2.2 ) dos exceed equivalent 15 mg/day diazepam ( Only patient use drug ) Patients significant risk develop severe adverse event . Patients medical condition would interfere assessment safety efficacy course trial , history condition . Patients receive follow treatment screen period : Reserpine Levodopa , dopamine receptor stimulant Monoamine oxidase inhibitor Psychostimulants Thyroid hormone , antithyroid drug Corticosteroids ( topical preparation ) Adrenaline All investigational unapproved agent ECT Light therapy For patient take lithium , valproate , carbamazepine within 3 day prior commencement investigational product administration , patient serum concentration lithium great 0.6 mmol/L , serum concentration valproate great 50 µg/mL , serum concentration carbamazepine great 4 µg/mL Patients judge diabetic blood glucose level ( judgment base use selfmonitoring blood glucose meter permissible ) , patient whose HbA1c 6.5 % high Patients history complication diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>